Dec 21, 2016 (Marketwired via COMTEX) — Consumers Looking for Zero THC Version of Real Scientific Hemp Oil (RSHO(TM)) Products Now Have Solution From First-Ever Approved Company
SAN DIEGO, CA–(Marketwired – December 21, 2016) – Medical Marijuana, Inc. (otc pink:MJNA), the first-ever publicly traded cannabis company in the United States, today announced that the Real Scientific Hemp Oil-X™ (RSHO-X™) product line is now being imported into Brazil through the company’s subsidiary, HempMeds Brasil™.
The RSHO-X™ product line was developed as the first tetrahydrocannabinol (THC)-free hemp oil product on the market. Originally developed to fit Mexico’s strict import regulations, RSHO-X™ was the first cannabis product ever legally imported into Mexico.
Recently, Dr Carlos Aguirre performed an informational study in Mexico where he used RSHO-X™ on various patients and children suffering from Epilepsy. Dr. Aguirre saw an average seizure reduction of 67% within his patient population, all with no adverse side effects. The results from this study will soon be published in Neurology Research International, an open access, peer-reviewed open access journal that publishes original research articles, review articles and clinical studies in all areas of neurology.
This RSHO-X product would be the first cannabis based product to actually qualify for World Anti-Doping standards.
“Our company was honored to create and distribute the first cannabis product to be approved for import and use in Brazil through medical prescription — we are excited to offer this important new hemp oil product line to the customers there,” said Dr. Stuart Titus, CEO of Medical Marijuana, Inc. “In line with our mission to bring cannabinoid access to all, RSHO-X™ opens up a growing market of customers looking to avoid THC but still experience the similar benefits awarded those who enjoy our traditional CBD hemp oil products.”
“HempMeds Brasil™ has been instrumental in creating access to medical cannabis in Brazil and we will continue to educate the medical community and regulatory agencies to make the process for obtaining cannabis products like RSHO-X™ easier,” added Dr. Titus.
RSHO-X™ is the preferred hemp oil supplement for those looking to completely avoid even trace amounts of THC. These RSHO-X™ users could range from:
First responders such as firefighters and police officers that deal with physical exertion and stress and must fit their employer’s restrictions on cannabis use.
Competing athletes who face restrictive cannabis testing policies for the sports’ governing bodies. RSHO-X™ in the first cannabidiol (CBD) hemp oil product able to pass the restriction on cannabis set forth by the World Anti-Doping Agency, enabling athletes to enjoy the benefits of CBD.
Parents looking to supplement their child with CBD hemp oil but wish to avoid exposing them to even trace amounts of THC, allowing them to benefit the balancing effects cannabinoids have on the human body.
About HempMeds Brasil™
HempMeds Brasil™ currently has three cannabis products approved for importation into Brazil as a prescription medication for Epilepsy, Parkinson’s and Chronic Pain. The company had the first-ever cannabis product allowed for import into Brazil and its products are currently subsidized by the Brazilian government, under their health care system, for all three medical indications listed above. HempMeds Brasil™ is working on additional approvals for multiple indications.
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.’s video statement, click here. Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
Public Relations Contact:
Andrew Hard Chief
P. 888-829- 0070
Corporate Business Contact:
Nicholas R. Massalas
Director of Business Development
Medical Marijuana, Inc. OTC Symbol: MJNA
Toll Free: 888-OTC- MJNA (888-682- 6562)
Investor Relations Contact:
Toll Free: (877) 964.6463
Office/Direct: (858) 264-6500
Email: [email protected]